A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
Abstract The lysosome-targeting chimera (LYTAC) strategy provided a very powerful tool for the degradation of membrane proteins. However, the synthesis of LYTACs, antibody-small molecule conjugates, is challenging. The ability of antibody-based LYTACs to penetrate solid tumor is limited as well, esp...
Saved in:
Main Authors: | Youmei Xiao, Zhuoying He, Wanqiong Li, Danhong Chen, Xiaoshuang Niu, Xin Yang, Wenxuan Zeng, Mengfan Wang, Yuzhen Qian, Ye Su, Feiyu Luo, Guanyu Chen, Juan Liu, Xinghua Sui, Xiuman Zhou, Yanfeng Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-025-56648-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving ferroptosis-mediated immunotherapy for colorectal cancer through lysosome-targeted photodynamic therapy
by: Zhian Chen, et al.
Published: (2025-04-01) -
Bicyclic peptide-enhanced covalent inhibitor of SARS-CoV-2 3CL protease
by: Qian Wang, et al.
Published: (2024-10-01) -
Engineered bacterial membrane biomimetic covalent organic framework as nano-immunopotentiator for cancer immunotherapy
by: Qi-Chao Yang, et al.
Published: (2025-05-01) -
Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01) -
Molecular aspects of cell-penetrating peptides: key amino acids, membrane partners, and non-covalent interactions
by: Walrant, Astrid, et al.
Published: (2025-01-01)